
NINTH MULTIDISCIPLINARY CONFERENCE ON DRUG RESEARCH

Editorial

The ninth Multidisciplinary Conference on Drug Research took place in very nice but somewhat isolated hotel and spa "Cztery Wiatry" ("Four Winds" on Chańcza artificial lake), near Szydłów, in Świętokrzyskie region, between 12 - 14 May, 2014. The conference gathered ca. 150 participants from many Polish scientific centers; most of them took active part in the program, which comprised 14 invited lectures, 19 short lectures and 134 poster presentations, arranged into two consecutive sessions. The opening lecture, devoted to the position of generic drugs in the present situation and future development of pharmaceutical sector, was delivered by prof. Łukasz Kaczmarek, CEO of Pharmaceutical Research Institute (IF). Details of the scientific program, which traditionally covered all aspects of drug research - from theory and design, through synthesis, to preclinical and clinical evaluation, published as Book of Abstracts (ISBN 83-89585-40-5), are also available on the website of PRI Pharmaceutical Research Institute - Instytut Farmaceutyczny). The organizers, considering informal obligation to consolidate drug research environment across various specialties and different affiliations their lasting duty, designated a panel discussion devoted to the future of the conference, in view of participants needs. It turned out that the majority would like to see continuation of MKNOL as an multidisciplinary event, supporting present design and format of the conference. Well, it certainly does not mean that everything is perfect. As we all know from everyday life - the economy is not. In the past, the organizers of MKNOL declared their support to participants, who wished to publish their proceedings in *Acta Poloniae Pharmaceutica - Drug Research*, in a dedicated issue. The journal, which is doing well in terms of impact factor and overall scientific trademark, has recently introduced dramatic publication policy changes, which resulted in introduction of publication charge. Under these rather suddenly declared new conditions, Pharmaceutical Research Institute (IF) is unable to continue unconditional support to all prospective authors of post - MKNOL publications. This time, from nearly 60 submitted contributions, only half could be qualified, based on the quality merit, to the sponsored pool of APP-DR November-December 2014 issue. Please accept our apologies. We will do our best to come to terms with the Editors of APP-DR over a new, clear policy concerning future publications of the MKNOL participants. Thank you for your continuing interest!

June 2014

Grzegorz Gryniewicz, Guest Editor